1.98
4.76%
+0.09
Compugen Ltd stock is currently priced at $1.98, with a 24-hour trading volume of 237.67K.
It has seen a +4.76% increased in the last 24 hours and a -25.00% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.91 pivot point. If it approaches the $2.00 resistance level, significant changes may occur.
Previous Close:
$1.89
Open:
$1.88
24h Volume:
237.67K
Market Cap:
$177.27M
Revenue:
-
Net Income/Loss:
$-18.75M
P/E Ratio:
-4.95
EPS:
-0.4
Net Cash Flow:
$-62.91M
1W Performance:
-2.46%
1M Performance:
-25.00%
6M Performance:
+183.26%
1Y Performance:
+219.35%
Compugen Ltd Stock (CGEN) Company Profile
Name
Compugen Ltd
Sector
Industry
Phone
972 3 765 8585
Address
Azrieli Center, Building D 26 Harokmim Street, Holon
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
May-26-20 | Resumed | JMP Securities | Mkt Outperform |
May-13-20 | Initiated | Stifel | Buy |
May-07-20 | Initiated | SVB Leerink | Outperform |
Apr-22-20 | Initiated | ROTH Capital | Buy |
Mar-24-20 | Initiated | SunTrust | Buy |
Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
Mar-29-18 | Initiated | Oppenheimer | Outperform |
Feb-01-16 | Resumed | Oppenheimer | Outperform |
Oct-15-15 | Initiated | FBR Capital | Outperform |
Apr-23-15 | Resumed | Jefferies | Buy |
Apr-21-15 | Initiated | Oppenheimer | Outperform |
Feb-07-14 | Initiated | MLV & Co | Buy |
Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
Zacks Investment Research
BOX Gears Up to Report Q4 Earnings: Here's What to Expect
Zacks Investment Research
Will Petrobras (PBR) Report Q4 Earnings Beat on Output Gains?
Zacks Investment Research
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
Zacks Investment Research
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
Zacks Investment Research
Baidu (BIDU) to Report Q4 Earnings: What's in the Offing?
Zacks Investment Research
Compugen Ltd Stock (CGEN) Financials Data
Compugen Ltd (CGEN) Net Income 2024
CGEN net income (TTM) was -$18.75 million for the quarter ending December 31, 2023, a +44.34% increase year-over-year.
Compugen Ltd (CGEN) Cash Flow 2024
CGEN recorded a free cash flow (TTM) of -$62.91 million for the quarter ending June 30, 2022.
Compugen Ltd (CGEN) Earnings per Share 2024
CGEN earnings per share (TTM) was -$0.21 for the quarter ending December 31, 2023, a +47.50% growth year-over-year.
About Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Cap:
|
Volume (24h):